These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7931248)

  • 1. Biochemical pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor.
    Rovei V; Caille D; Curet O; Ego D; Jarreau FX
    J Neural Transm Suppl; 1994; 41():339-47. PubMed ID: 7931248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile.
    Caille D; Bergis OE; Fankhauser C; Gardes A; Adam R; Charieras T; Grosset A; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):265-77. PubMed ID: 8613929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical profile of befloxatone, a new reversible MAO-A inhibitor.
    Curet O; Damoiseau-Ovens G; Sauvage C; Sontag N; Avenet P; Depoortere H; Caille D; Bergis O; Scatton B
    J Affect Disord; 1998 Dec; 51(3):287-303. PubMed ID: 10333983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile.
    Curet O; Damoiseau G; Aubin N; Sontag N; Rovei V; Jarreau FX
    J Pharmacol Exp Ther; 1996 Apr; 277(1):253-64. PubMed ID: 8613928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacology of befloxatone: a brief review.
    Rosenzweig P; Patat A; Curet O; Durrieu G; Dubruc C; Zieleniuk I; Legangneux E
    J Affect Disord; 1998 Dec; 51(3):305-12. PubMed ID: 10333984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects.
    Patat A; Berlin I; Durrieu G; Armand P; Fitoussi S; Molinier P; Caille P
    J Clin Pharmacol; 1995 Jun; 35(6):633-43. PubMed ID: 7665725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats.
    Curet O; Damoiseau G; Labaune JP; Rovel V; Jarreau FX
    J Neural Transm Suppl; 1994; 41():349-55. PubMed ID: 7931249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone.
    Bottlaender M; Dolle F; Guenther I; Roumenov D; Fuseau C; Bramoulle Y; Curet O; Jegham J; Pinquier JL; George P; Valette H
    J Pharmacol Exp Ther; 2003 May; 305(2):467-73. PubMed ID: 12606609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute inhibition of cardiac monoamine oxidase A after tobacco smoke inhalation: validation study of [11C]befloxatone in rats followed by a positron emission tomography application in baboons.
    Valette H; Bottlaender M; Dollé F; Coulon C; Ottaviani M; Syrota A
    J Pharmacol Exp Ther; 2005 Jul; 314(1):431-6. PubMed ID: 15833896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A reversible monoamine oxidase A inhibitor, befloxatone: structural approach of its mechanism of action.
    Wouters J; Moureau F; Evrard G; Koenig JJ; Jegham S; George P; Durant F
    Bioorg Med Chem; 1999 Aug; 7(8):1683-93. PubMed ID: 10482460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of dehydropirlindole and other compounds on rat brain monoamine oxidase type A.
    Gerardy J; Dresse A
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 Jan; 26(1):75-9. PubMed ID: 11853123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.
    Dolle F; Valette H; Bramoulle Y; Guenther I; Fuseau C; Coulon C; Lartizien C; Jegham S; George P; Curet O; Pinquier JL; Bottlaender M
    Bioorg Med Chem Lett; 2003 May; 13(10):1771-5. PubMed ID: 12729662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor.
    Rosenzweig P; Patat A; Zieleniuk I; Cimarosti I; Allain H; Gandon JM
    Clin Pharmacol Ther; 1998 Aug; 64(2):211-22. PubMed ID: 9728902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo characterization of T-794, a novel reversible inhibitor of monoamine oxidase-A, as an antidepressant with a wide safety margin.
    Kato M; Katayama T; Iwata H; Yamamura M; Matsuoka Y; Narita H
    J Pharmacol Exp Ther; 1998 Mar; 284(3):983-90. PubMed ID: 9495858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of befloxatone, a reversible selective monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects.
    Warot D; Berlin I; Patat A; Durrieu G; Zieleniuk I; Puech AJ
    J Clin Pharmacol; 1996 Oct; 36(10):942-50. PubMed ID: 8930782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and early clinical evaluation of selective inhibitors of monoamine oxidase.
    Palfreyman MG; McDonald IA; Bey P; Schechter PJ; Sjoerdsma A
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(6):967-87. PubMed ID: 3266532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinal metabolism of tyramine by both forms of monoamine oxidase in the rat.
    Benedetti MS; Boucher T; Carlsson A; Fowler CJ
    Biochem Pharmacol; 1983 Jan; 32(1):47-52. PubMed ID: 6830619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission.
    Haddjeri N; De Montigny C; Curet O; Blier P
    Eur J Pharmacol; 1998 Feb; 343(2-3):179-92. PubMed ID: 9570466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
    Patat A; le Coz F; Dubruc C; Gandon JM; Durrieu G; Cimarosti I; Jezequel S; Curet O; Zieleniuk I; Allain H; Rosenzweig P
    J Clin Pharmacol; 1996 Mar; 36(3):216-29. PubMed ID: 8690815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.